Products and Services
A high-standard, high-tech, and international CDMO innovation platform
Nucleotide Intermediates
Advanced Pharmaceutical Intermediates
Molecular Building Blocks
Advanced Dental Material Adhesives
Other Intermediates
Customized Synthesis Services
About Us
Research and Development, Manufacturing, Agency, Sales
Wuhan Wandou Technology Co., Ltd. is a national high-tech enterprise specializing in the R&D and industrialization of key building blocks and critical materials for specialized pharmaceutical synthesis.
Guided by a long-term vision, we engage in value co-creation with domestic innovative pharmaceutical companies and R&D institutes. By providing pivotal chemical intermediates and custom manufacturing services that are critical to R&D success, we have established ourselves as a key enabler in accelerating the journey of innovative drugs from the laboratory to the market.
Our product portfolio includes:Nucleotide Intermediates: Such as Dibenzyl N,N-Diisopropylphosphoramidite (CAS: 108549-23-1) and Diethyl Allylphosphonate (CAS: 1067-87-4).Advanced Pharmaceutical Intermediates: Including 4-(Chloromethyl)benzyl alcohol (CAS: 16473-35-1) and 1,4,8,11-Tetraazacyclotetradecane (CAS: 295-37-4).Molecular Building Blocks: Such as 1,4,7-Triazacyclononane (CAS: 4730-54-5) and 1-(2-Pyridyl)thiourea (CAS: 14294-11-2).Advanced Dental Material Adhesives: Such as 10-MDP (CAS: 85590-00-7).Our products have been distributed worldwide and have earned high acclaim from our customers.
We are committed to a culture where quality and integrity are the cornerstones, and innovation and service are the driving forces. Through standardized management and a continuously improving product system, we are dedicated to delivering core value to global drug discovery and manufacturing.
News Updates
-
In 2025, Novo Nordisk announced results from two large-scale Phase III clinical trials (EVOKE and EVOKE+) of its GLP-1 receptor agonist semaglutide for early symptomatic Alzheimer's disease. The results showed that compared to placebo, semaglutide failed to significantly slow patients' cognitive decline and did not meet the trials' primary endpoints.1. Trial Basics2. Detailed Trial ResultsPrimary Endpoint Not Met: After 104 weeks of treatment, the reduction in CDR-SB scores for the semaglutide group showed no statistically significant difference compared to the placebo group. This means semaglutide failed to demonstrate successful efficacy on the most critical goal: slowing the clinical progression of the disease.Contradictory Biomarker Data: Despite the failed clinical endpoint, an important "signal" was observed: the semaglutide treatment group... -
This article is sourced from The Lancet regional health AmericaThe 85th Scientific Sessions of the American Diabetes Association (ADA) was held in Chicago, IL, USA, from June 20 to June 23, 2025. Below is a summary of topics covered in some of the most exciting sessions.A comparison of the benefits of newer drugs for type 2 diabetesIn this session, Dr. Karol Watson (University of California, Los Angeles, CA, USA) discussed the benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). According to Dr. Watson, to date, there is no strong evidence that dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RAs improve cardiovascular disease. In contrast, there is compelling evidence supporting the benefit of GLP-1 RAs on reducing stroke, mortality, and kidney disease. Dr. Watson emphasized that sodium-glucose co...
-
Dibenzyl Diisopropylphosphoramidite, more commonly known by its systematic name, is an important organophosphorus compound.Item DetailsChinese Name:Diphenyl N,N'-diisopropylphosphoramidite (also commonly called: Dibenzyl Diisopropylphosphoramidite)English Name:Dibenzyl DiisopropylphosphoramiditeCAS Numbe:108549-23-1Molecular Formula:C₂₀H₂₈NO₂PMolecular Weight:345.42 g/molAppearance:Colorless to pale yellow oily liquidCharacteristics:Air- and moisture-sensitive; typically requires sealed storage at 2-8°CPrimary ApplicationsDibenzyl Diisopropylphosphoramidite plays a key role in organic synthesis and materials science, primarily serving as a phosphoramidation reagent and organic synthetic intermediate.Pharmaceutical and Chemical Industry:Antibiotic Synthesis: It is used as a phosphorylating reagent in the process of preparing the antibiot...
-
This article is sourced from The Lancet MicrobeNov 18–24, 2025, marks the 10th edition of World AMR Awareness Week, an annual campaign led by WHO with the goal to increase awareness of global antimicrobial resistance (AMR) and to encourage best practices. Much has happened over this past decade—a pandemic, a seminal paper directly attributing over 1 million deaths each year to bacterial AMR, and a shift to One Health thinking—but the next decade will be pivotal in translating awareness into sustained action, innovative solutions, and global leadership to truly curb the threat of AMR.Despite increasing global awareness, progress in combating AMR has been slow. Two WHO reports, published on Oct 2, describe how the pipelines of antibacterial agents and bacterial diagnostics remain insufficient to meet urgent global needs. Both reports ca...
